dc.contributor.author | Jones, Robin Lewis | en |
dc.contributor.author | Constantinidou, Anastasia | en |
dc.contributor.author | Olmos, David | en |
dc.contributor.author | Thway, K. | en |
dc.contributor.author | Fisher, Cyril | en |
dc.contributor.author | Al-Muderis, Omar | en |
dc.contributor.author | Scurr, Michelle R. | en |
dc.contributor.author | Judson, Ian Robert | en |
dc.creator | Jones, Robin Lewis | en |
dc.creator | Constantinidou, Anastasia | en |
dc.creator | Olmos, David | en |
dc.creator | Thway, K. | en |
dc.creator | Fisher, Cyril | en |
dc.creator | Al-Muderis, Omar | en |
dc.creator | Scurr, Michelle R. | en |
dc.creator | Judson, Ian Robert | en |
dc.date.accessioned | 2018-06-22T09:53:42Z | |
dc.date.available | 2018-06-22T09:53:42Z | |
dc.date.issued | 2012 | |
dc.identifier.uri | https://gnosis.library.ucy.ac.cy/handle/7/41979 | |
dc.description.abstract | Background: Epithelioid sarcoma is a rare soft tissue sarcoma subtype. The response of this disease to chemotherapy is not well described. The aim of this study was to investigate the response rate and progression-free survival in a series of epithelioid sarcoma patients treated with chemotherapy at a single referral center. Methods: A retrospective search of a prospectively maintained database was made to identify epithelioid sarcoma patients treated with chemotherapy between 1990 and 2009. Radiological response and histological diagnosis were re-reviewed for this study. Results: Twenty-one epithelioid sarcoma patients treated with chemotherapy were identified; follow-up data on palliative chemotherapy was available on 20 of these patients. The median age was 36.5 years (range, 17.4 to 64.8 y) and the male/female ratio was 19:2. Ten patients (50%) were treated with single-agent anthracycline, 9 patients (45%) were treated with a combination therapy (anthracycline and ifosfamide), and 1 patient received trabectedin (5%). Three patients achieved a partial response, 12 had stable disease, and 5 progressed. The median progression-free survival was 29 weeks (95% confidence interval [CI]: 23-35). Seven and 3 patients received second-line and third-line palliative chemotherapy, respectively. The median overall survival from commencing palliative chemotherapy in our series was 51 weeks (95% confidence interval; 29-73). Conclusions: Systemic chemotherapy provides satisfactory palliation in patients with epithelioid sarcoma. However, this is an aggressive disease, responses to chemotherapy are of short duration and there is a need for more effective novel therapies in the treatment of this condition. Copyright © 2012 by Lippincott Williams & Wilkins. | en |
dc.language.iso | eng | en |
dc.source | American Journal of Clinical Oncology: Cancer Clinical Trials | en |
dc.subject | Chemotherapy | en |
dc.subject | Epithelioid sarcoma | en |
dc.subject | Response rate | en |
dc.subject | Time to progression | en |
dc.title | Role of palliative chemotherapy in advanced epithelioid sarcoma | en |
dc.type | info:eu-repo/semantics/article | |
dc.identifier.doi | 10.1097/COC.0b013e3182118cf7 | |
dc.description.volume | 35 | |
dc.description.issue | 4 | |
dc.description.startingpage | 351 | |
dc.description.endingpage | 357 | |
dc.author.faculty | Ιατρική Σχολή / Medical School | |
dc.author.department | Ιατρική Σχολή / Medical School | |
dc.type.uhtype | Article | en |
dc.contributor.orcid | Constantinidou, Anastasia [0000-0001-5316-7574] | |
dc.contributor.orcid | Judson, Ian Robert [0000-0002-4766-5304] | |
dc.gnosis.orcid | 0000-0001-5316-7574 | |
dc.gnosis.orcid | 0000-0002-4766-5304 | |